Clinical Trial Update: Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating panobinostat (LBH589) for recurrent malignant gliomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Neurological Surgery, P.C. | Conditions: Recurrent Malignant Gliomas | Phase 2 | Status: TERMINATED